Clearmind Medicine Advances Fight Against Cocaine Addiction with U.S. Patent Application

Clearmind Medicine Inc. announced the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy, aimed at treating cocaine addiction. This application strengthens the company's intellectual property portfolio and highlights the potential of MEAI to address a significant unmet medical need. Cocaine use disorder affects millions globally, with no FDA-approved pharmacological treatment currently available. The global market for cocaine addiction treatment is estimated at $1.36 billion in 2025 and is projected to grow to $2.03 billion by 2032. MEAI is designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. The company also reported the conversion of $1,045,062 of outstanding amounts due under convertible promissory notes into 885,000 common shares.